A Phase 3 interventional study of celecoxib and tramadol HCL in Low Back Pain, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 60 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-21.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 711 studies in Low Back Pain with a site in United States — 99 open to participants now, 125 under way, 3 of them phase 3. Low Back Pain · United States.
Among the 711 studies in Low Back Pain with a site in United States, this one is the 26th largest by enrollment of the 623 interventional ones that give a count, is one of 21 that started in 2008, is one of 62 in phase 3, and was the 86th registered.
2,926 studies on the registry are indexed under Low Back Pain; 579 are open to participants now.
Browse Low Back Pain studies →99 of the 711 studies in Low Back Pain with a site in United States are open now. Recruiting first, the newest first:
New York Medical College · Sites in United States
Ages 18+
Loma Linda University · Sites in United States
Ages 18–65 · Healthy volunteers
Weill Medical College of Cornell University · Sites in United States
Ages 18+
University of Central Florida · Sites in United States
Ages 18–65
Eli Lilly and Company · Sites in United States, Puerto Rico
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
711 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 35 · Phase 2 80 · Phase 3 73 · Phase 4 50
First in 1977; this study’s year is marked. 21 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 802 is above the median of 60 across 2,366 interventional studies indexed under Low Back Pain.
Median enrollment 79 across the 623 interventional studies, 89 across the 84 observational. Of the 513 that completed or were terminated, 207 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
156 of 711 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
Viatris Inc. has 8 studies filed under Low Back Pain — fewer than ten, so there is no comparison to draw.
51 of the studies in Low Back Pain with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07254806Phase 3DiscGenics, Inc.A Study to Evaluate the Effectiveness of IDCT (Intradiscal Cell Therapy) in Subjects With One Level, Symptomatic Mild to Moderate Lumbar Degenerative Disc Disease | 2027-11-24 |
| NCT07125027National University of Natural MedicineA Multicomponent Intervention for Patients With Lumbosacral Radiculopathy: Move-MORE | 2026-11 |
| NCT07652944Joe X. ZhangTrial to Test the Efficacy of Using Magnetic Fields to Stimulate the Back to Treat Chronic Lower Back Pain. | 2026-11 |
| NCT04730700University of Kansas Medical CenterEvaluation of Multi-Tined Expandable Electrode (MEE) Efficacy and Safety in Treatment of Lumbar Facet Arthropathy by Radiofrequency Neurotomies Compared to Conservative Medical Management. | 2026-11-30 |
| NCT06007976Mayo ClinicLLLT to Reduce Low Back Pain | 2026-12 |
Add all 51 to your calendar (.ics) → With an account.
Among the 711 studies in Low Back Pain with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To compare the analgesic effectiveness of celecoxib and tramadol in subjects with Chronic Low Back Pain measured by the Numerical Rating Scale (NRS-Pain) at Week 6
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: celecoxib
Drug: tramadol HCL
200 mg capsules BID for 6 weeks
50 mg capsules QID for 6 weeks
Treatment Responders Based on the Numerical Rating Scale-Pain (NRS-Pain)
A subject who met the following criteria was considered as a successful responder at Week 6: completed 6 weeks of treatment with study medication and had a 30% improvement from Baseline to Week 6/ET on the NRS-Pain. NRS-Pain scale assessed the severity of a subject's lower back pain on a scale of 0 (No pain) and 10 (Worst possible pain).
Time frame: Week 6 or Early Termination (ET)
Change From Baseline in Severity of Chronic Low Back Pain as Measured by NRS-Pain
NRS-Pain scale assessed the severity of a subject's lower back pain on a scale of 0 (No pain) and 10 (Worst possible pain). NRS-Pain scale: Change = mean score at Week 6/ET minus mean score at Baseline.
Time frame: Baseline, Week 6/ET
Change From Baseline in Severity of Low Back Pain as Measured by Visual Analogue Scale (VAS)
VAS was a 100 millimeter (mm) scale that subjects used to assess the severity of their lower back pain. Based on the following question, "During the past day, how much back pain did you have?", the subject was instructed to place a vertical line on the VAS to indicate the magnitude of his/her lower back pain. 0 mm = no pain and 100 mm = worst possible pain. VAS: Change = mean score at Week 6/ET minus mean score at Baseline.
Time frame: Baseline, Week 6/ET
Patient's Global Assessment of Disease Activity
Number of subjects with a graded level of disease activity using the Patient's Global Assessment of Disease Activity 5-point scale (1=very good, 2=good, 3=fair, 4=poor, and 5=very poor). Subjects were classified as "Improved" if their assessment reduced at least 2 grades from baseline or if their assessment changed to Grade 1 (Very Good). Subjects were classified as "Worsened" if their assessment increased at least 2 grades from baseline or if their assessment changed to Grade 5 (Very Poor). Subjects were classified as "No Change" otherwise.
Time frame: Week 6/ET
Physician's Global Assessment of Disease Activity
Number of subjects with a physician's grading of disease activity using the Physician's Global Assessment of Disease Activity 5-point scale ((1=very good, 2=good, 3=fair, 4=poor, and 5=very poor). Subjects were classified as "Improved" if their assessment reduced at least 2 grades from baseline or if their assessment changed to Grade 1 (Very Good). Subjects were classified as "Worsened" if their assessment increased at least 2 grades from baseline or if their assessment changed to Grade 5 (Very Poor). Subjects were classified as "No Change" otherwise.
Time frame: Week 6/ET
Change From Baseline in Roland-Morris Disability Questionnaire (RMDQ) Total Score
Each subject assessed his/her own disability due to low back pain using the RMDQ worksheet, which consisted of 24 statements of disability. The RMDQ total score was calculated as the total number of statements that were checked; the RMDQ total scores could have ranged from 0 to 24, with higher scores indicating greater disability. RMDQ: Change = mean score at Week 6/ET minus mean score at Baseline.
Time frame: Baseline, Week 6/ET
Change From Baseline in Modified Brief Pain Inventory (m-BPI-sf)
m-BPI-sf scale assessed pain severity (0 = no pain to 10 = worst possible pain), and pain interference of functional activities (0 = does not interfere to 10 = completely interferes) during the 24 hour follow-up period. Subjects indicated: how much pain now; worst pain; average level of pain; how much pain interfered with general activity, mood, walking ability, relations with other people, sleep, normal work (including housework), and enjoyment of life. m-BPI-sf: Change = mean score at Week 6/ET minus mean score at Baseline.
Time frame: Baseline, Week 6/ET
Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale
MOS sleep scale included the following attributes: sleep disturbance, snoring, awaken shortness of breath or headache, quantity of sleep, sleep adequacy, somnolence, Sleep Problem Index I, and Sleep Problem Index II. Score ranged from 0-100, with a higher score indicating more of the scale attribute (e.g., more sleep disturbance, etc.). A negative change indicated subject improvement. MOS sleep scale: Change = mean score at Week 6/ET minus mean score at Baseline.
Time frame: Baseline, Week 6/ET
Number of Subjects With Change From Baseline in MOS Optimal Sleep Scale Scores
The Optimal Scale is scaled from 0 or 1 with 1 indicating 7 or 8 hours of sleep per night and 0 otherwise. Number of subjects with change of improvement (0 to 1), no change (1 to 1 or 0 to 0), or worsening (1 to 0) from baseline as indicated by the MOS Optimal sleep scale.
Time frame: Baseline, Week 6/ET
Change From Baseline in Work Limitations Questionnaire (WLQ)
The WLQ included the following: Time Scale, Physical Scale, Output Scale, Mental-Interpersonal Scale, and Index Scale. The scales ranged from 0 (Limited none of the time) to 100 (Limited all of the time). A negative change indicated subject improvement.
Time frame: Baseline, Week 6/ET
Patient's Global Evaluation of Study Medication
Number of subjects with an overall response to study medication of poor, fair, good, very good, and excellent.
Time frame: Weeks 1, 3, and 6/ET
Patient's Satisfaction Questionnaire (With Pain Relief Scale)
Number of subjects at varying levels of pain relief (1 = very dissatisfied to 10 = very satisfied).
Time frame: Week 6/ET
Patient's Satisfaction Questionnaire (With Walking and Bending Ability Scale)
Number of subjects at varying levels of pain relief (1 = very dissatisfied to 10 = very satisfied).
Time frame: Week 6/ET
Chronic Low Back Pain Responders Based on VAS, Patient's Global, and RMDQ
Subjects were successful responders if they had: \> = 30% improvement from baseline to final visit in VAS assessment (as identified by 100 millimeter scale); \> = 30% improvement from baseline to final visit in Patient's Global assessment (classified as improved if assessment reduced at least 2 grades from baseline or if assessment changed to Grade 1, worsened if assessment increased at least 2 grades from baseline or if assessment changed to Grade 5, or no change; and \< 20% worsening from baseline to final visit in RMDQ assessment (lower scores indicated greater disability).
Time frame: Week 6/ET
| Milestone | Celecoxib | Tramadol HCL |
|---|---|---|
| Started | 398 | 404 |
| Received treatment | 396 | 396 |
| Completed | 342 | 294 |
| Not completed | 56 | 110 |
| Withdrew: Adverse event | 21 | 59 |
| Withdrew: Lack of efficacy | 4 | 7 |
| Withdrew: Lost to follow-up | 13 | 10 |
| Withdrew: Other | 9 | 14 |
| Withdrew: Withdrawal by subject | 7 | 12 |
| Withdrew: Randomized but did not receive treatment | 2 | 8 |
A subject who met the following criteria was considered as a successful responder at Week 6: completed 6 weeks of treatment with study medication and had a 30% improvement from Baseline to Week 6/ET on the NRS-Pain. NRS-Pain scale assessed the severity of a subject's lower back pain on a scale of 0 (No pain) and 10 (Worst possible pain).
| participants | Celecoxib | Tramadol HCL |
|---|---|---|
| Responders | 254 | 218 |
| Non-responders | 142 | 178 |
NRS-Pain scale assessed the severity of a subject's lower back pain on a scale of 0 (No pain) and 10 (Worst possible pain). NRS-Pain scale: Change = mean score at Week 6/ET minus mean score at Baseline.
| scores on a scale | Celecoxib | Tramadol HCL |
|---|---|---|
| Change From Baseline in Severity of Chronic Low Back Pain as Measured by NRS-Pain | -3.38 ± 0.12 | -3.25 ± 0.13 |
VAS was a 100 millimeter (mm) scale that subjects used to assess the severity of their lower back pain. Based on the following question, "During the past day, how much back pain did you have?", the subject was instructed to place a vertical line on the VAS to indicate the magnitude of his/her lower back pain. 0 mm = no pain and 100 mm = worst possible pain. VAS: Change = mean score at Week 6/ET minus mean score at Baseline.
| mm | Celecoxib | Tramadol HCL |
|---|---|---|
| Change From Baseline in Severity of Low Back Pain as Measured by Visual Analogue Scale (VAS) | -34.78 ± 1.33 | -34.27 ± 1.42 |
Number of subjects with a graded level of disease activity using the Patient's Global Assessment of Disease Activity 5-point scale (1=very good, 2=good, 3=fair, 4=poor, and 5=very poor). Subjects were classified as "Improved" if their assessment reduced at least 2 grades from baseline or if their assessment changed to Grade 1 (Very Good). Subjects were classified as "Worsened" if their assessment increased at least 2 grades from baseline or if their assessment changed to Grade 5 (Very Poor). Subjects were classified as "No Change" otherwise.
| participants | Celecoxib | Tramadol HCL |
|---|---|---|
| Improved | 108 | 107 |
| No Change | 264 | 259 |
| Worsened | 3 | 1 |
Number of subjects with a physician's grading of disease activity using the Physician's Global Assessment of Disease Activity 5-point scale ((1=very good, 2=good, 3=fair, 4=poor, and 5=very poor). Subjects were classified as "Improved" if their assessment reduced at least 2 grades from baseline or if their assessment changed to Grade 1 (Very Good). Subjects were classified as "Worsened" if their assessment increased at least 2 grades from baseline or if their assessment changed to Grade 5 (Very Poor). Subjects were classified as "No Change" otherwise.
| participants | Celecoxib | Tramadol HCL |
|---|---|---|
| Improved | 113 | 102 |
| No Change | 253 | 258 |
| Worsened | 2 | 1 |
Each subject assessed his/her own disability due to low back pain using the RMDQ worksheet, which consisted of 24 statements of disability. The RMDQ total score was calculated as the total number of statements that were checked; the RMDQ total scores could have ranged from 0 to 24, with higher scores indicating greater disability. RMDQ: Change = mean score at Week 6/ET minus mean score at Baseline.
| scores on a scale | Celecoxib | Tramadol HCL |
|---|---|---|
| Change From Baseline in Roland-Morris Disability Questionnaire (RMDQ) Total Score | -4.90 ± 0.26 | -4.45 ± 0.25 |
m-BPI-sf scale assessed pain severity (0 = no pain to 10 = worst possible pain), and pain interference of functional activities (0 = does not interfere to 10 = completely interferes) during the 24 hour follow-up period. Subjects indicated: how much pain now; worst pain; average level of pain; how much pain interfered with general activity, mood, walking ability, relations with other people, sleep, normal work (including housework), and enjoyment of life. m-BPI-sf: Change = mean score at Week 6/ET minus mean score at Baseline.
| scores on a scale | Celecoxib | Tramadol HCL |
|---|---|---|
| How Much Pain Now | -2.87 ± 0.12 | -2.88 ± 0.13 |
| Worst Pain in Past 24 Hours | -2.84 ± 0.13 | -2.87 ± 0.13 |
| Average Pain in Past 24 Hours | -2.64 ± 0.11 | -2.59 ± 0.13 |
| Pain Interfered With General Activity | -2.62 ± 0.12 | -2.57 ± 0.13 |
| Pain Interfered With Mood | -2.38 ± 0.14 | -2.25 ± 0.15 |
| Pain Interfered With Walking Activity | -2.26 ± 0.13 | -2.36 ± 0.13 |
| Pain Interfered With Relations With Others | -1.79 ± 0.13 | -1.74 ± 0.14 |
| Pain Interfered With Sleep | -2.52 ± 0.13 | -2.51 ± 0.15 |
| Pain Interfered With Normal Work | -2.57 ± 0.13 | -2.46 ± 0.15 |
| Pain Interfered With Enjoyment of Life | -2.43 ± 0.14 | -2.43 ± 0.15 |
| Pain Interference Subscale | -2.37 ± 0.11 | -2.33 ± 0.12 |
MOS sleep scale included the following attributes: sleep disturbance, snoring, awaken shortness of breath or headache, quantity of sleep, sleep adequacy, somnolence, Sleep Problem Index I, and Sleep Problem Index II. Score ranged from 0-100, with a higher score indicating more of the scale attribute (e.g., more sleep disturbance, etc.). A negative change indicated subject improvement. MOS sleep scale: Change = mean score at Week 6/ET minus mean score at Baseline.
| scores on a scale | Celecoxib | Tramadol HCL |
|---|---|---|
| Sleep Disturbance (n=374, 367) | -17.91 ± 1.23 | -16.34 ± 1.17 |
| Snoring (n=372, 365) | -7.53 ± 1.31 | -5.10 ± 1.28 |
| Awaken Shortness of Breath, Headache (n=374, 367) | -8.61 ± 1.27 | -6.21 ± 1.34 |
| Quantity of Sleep (n=373, 365) | 0.00 ± 0.23 | 0.58 ± 0.28 |
| Sleep Adequacy (n=373, 367) | 7.32 ± 1.48 | 9.67 ± 1.34 |
| Somnolence (n=374, 366) | -9.63 ± 1.05 | -7.01 ± 1.16 |
| Sleep Problem Index I (n=373, 367) | -11.59 ± 0.96 | -10.54 ± 0.92 |
| Sleep Problem Index II (n=373, 367) | -12.97 ± 0.94 | -11.82 ± 0.89 |
The Optimal Scale is scaled from 0 or 1 with 1 indicating 7 or 8 hours of sleep per night and 0 otherwise. Number of subjects with change of improvement (0 to 1), no change (1 to 1 or 0 to 0), or worsening (1 to 0) from baseline as indicated by the MOS Optimal sleep scale.
| participants | Celecoxib | Tramadol HCL |
|---|---|---|
| 0 to 1 (Improvement) | 82 | 74 |
| 1 to 1 (No change) | 94 | 70 |
| 0 to 0 (No change) | 171 | 192 |
| 1 to 0 (worsening) | 26 | 29 |
The WLQ included the following: Time Scale, Physical Scale, Output Scale, Mental-Interpersonal Scale, and Index Scale. The scales ranged from 0 (Limited none of the time) to 100 (Limited all of the time). A negative change indicated subject improvement.
| scores on a scale | Celecoxib | Tramadol HCL |
|---|---|---|
| Time Scale (n=241, 239) | -11.55 ± 1.65 | -13.58 ± 1.52 |
| Physical Scale (n=270, 254) | -13.68 ± 1.52 | -12.65 ± 1.45 |
| Output Scale (n=256, 246) | -11.44 ± 1.54 | -11.69 ± 1.70 |
| Mental-Interpersonal Scale (n=266, 252) | -9.06 ± 1.35 | -9.54 ± 1.51 |
| Index Scale (n=223, 220) | -3.10 ± 0.36 | -3.14 ± 0.37 |
Number of subjects with an overall response to study medication of poor, fair, good, very good, and excellent.
| participants | Celecoxib | Tramadol HCL |
|---|---|---|
| Week 1, Excellent | 46 | 38 |
| Week 1, Very Good | 97 | 83 |
| Week 1, Good | 126 | 137 |
| Week 1, Fair | 78 | 57 |
| Week 1, Poor | 23 | 18 |
| Week 3, Excellent | 52 | 41 |
| Week 3, Very Good | 104 | 97 |
| Week 3, Good | 122 | 105 |
| Week 3, Fair | 53 | 51 |
| Week 3, Poor | 23 | 14 |
| Week 6/ET, Excellent | 91 | 68 |
| Week 6/ET, Very Good | 123 | 112 |
| Week 6/ET, Good | 76 | 90 |
| Week 6/ET, Fair | 51 | 51 |
| Week 6/ET, Poor | 32 | 44 |
Number of subjects at varying levels of pain relief (1 = very dissatisfied to 10 = very satisfied).
| participants | Celecoxib | Tramadol HCL |
|---|---|---|
| 1 | 23 | 22 |
| 2 | 15 | 18 |
| 3 | 22 | 19 |
| 4 | 22 | 20 |
| 5 | 44 | 30 |
| 6 | 23 | 29 |
| 7 | 21 | 39 |
| 8 | 63 | 56 |
| 9 | 53 | 62 |
| 10 | 87 | 69 |
Number of subjects at varying levels of pain relief (1 = very dissatisfied to 10 = very satisfied).
| participants | Celecoxib | Tramadol HCL |
|---|---|---|
| 1 | 24 | 15 |
| 2 | 16 | 22 |
| 3 | 19 | 20 |
| 4 | 31 | 33 |
| 5 | 35 | 40 |
| 6 | 32 | 30 |
| 7 | 35 | 37 |
| 8 | 55 | 46 |
| 9 | 56 | 77 |
| 10 | 70 | 44 |
Subjects were successful responders if they had: \> = 30% improvement from baseline to final visit in VAS assessment (as identified by 100 millimeter scale); \> = 30% improvement from baseline to final visit in Patient's Global assessment (classified as improved if assessment reduced at least 2 grades from baseline or if assessment changed to Grade 1, worsened if assessment increased at least 2 grades from baseline or if assessment changed to Grade 5, or no change; and \< 20% worsening from baseline to final visit in RMDQ assessment (lower scores indicated greater disability).
| participants | Celecoxib | Tramadol HCL |
|---|---|---|
| Responders | 213 | 196 |
| Non-responders | 183 | 200 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Celecoxib | — | — | — |
| Tramadol HCL | — | — | — |
| Event | Celecoxib | Tramadol HCL |
|---|---|---|
| Coronary artery bypassSurgical and medical procedures | 1/396 | 0/396 |
| Event | Celecoxib | Tramadol HCL |
|---|---|---|
| NauseaGastrointestinal disorders | 31/396 | 70/396 |
| HeadacheNervous system disorders | 41/396 | 54/396 |
| DizzinessNervous system disorders | 19/396 | 53/396 |
| SomnolenceNervous system disorders | 20/396 | 44/396 |
| VomitingGastrointestinal disorders | 5/396 | 28/396 |
| ConstipationGastrointestinal disorders | 8/396 | 25/396 |
| PruritusSkin and subcutaneous tissue disorders | 2/396 | 23/396 |
| Dry mouthGastrointestinal disorders | 6/396 | 20/396 |
| Age, Customized(participants) | Celecoxib | Tramadol HCL | Total |
|---|---|---|---|
| 18 to 44 years | 164 | 167 | 331 |
| 45 to 64 years | 191 | 182 | 373 |
| > = 65 years | 41 | 47 | 88 |
| Sex: Female, Male(Participants) | Celecoxib | Tramadol HCL | Total |
|---|---|---|---|
| Female | 237 | 213 | 450 |
| Male | 159 | 183 | 342 |
The record gives a start of Jan 2008, a primary completion of Sep 2008 and a completion of Sep 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2009, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Celecoxib
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →